Overview

Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects

Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The study is designed to determine the safety, tolerability, and pharmacokinetics in healthy subjects with multiple intravenous administration of the neuroprotectant YC-6 compared to placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Guangzhou Cellprotek Pharmaceutical Co., Ltd.
Collaborator:
Xiuhe Medical Technique Co.,Ltd.